# exteRNA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/externa

- Industry: Biotechnology
- Headquarters: Melbourne, Australia
- Website: www.externabio.com/
- Total disclosed funding: $11M
- Latest round: Seed (Oct 29, 2024)
- Investors on record: 4

## About

Based in Melbourne, Australia, exteRNA is a biotechnology firm focused on innovative solutions that enhance healthcare outcomes through advanced biomanufacturing and biological research services.Founded in 2024 in Melbourne, Australia, exteRNA specializes in biotechnological services targeting pharmaceutical and biotechnology companies. In October 2024, the company raised USD 11 million in Seed funding, led by IP Group, marking its first financing round. The firm has secured a total of USD 11 million in funding, with its latest deal involving notable investors such as Hostplus, Tin Alley Ventures, and Walter And Eliza Hall Institute Of Medical Research.Externa specializes in innovative biotechnological solutions aimed at enhancing healthcare outcomes. Their core product offerings include advanced biological research services and cutting-edge biomanufacturing processes that support the development of therapeutics and diagnostics. These services cater primarily to pharmaceutical and biotechnology companies looking to optimize their research and development pipelines. The company's products address critical challenges in drug development, such as increasing efficiency, reducing costs, and accelerating time-to-market for new treatments. Externa serves a diverse clientele across North America and Europe, focusing on established pharmaceutical firms and emerging biotech startups requiring high-quality biological solutions to enhance their product offerings.Externa operates on a B2B transactional model, facilitating partnerships with pharmaceutical and biotechnology companies that leverage their biotechnological services. Revenue is generated primarily through contractual agreements for customized research and development projects, with clients paying based on service tiers and project scope. These transactions often involve multi-year contracts, where clients agree to pay for specific milestones in the development process. Flagship services, aimed at optimizing biomanufacturing and biological research, form the backbone of Externa's revenue streams, encompassing tailored solutions designed to meet the unique needs of each client. Through this model, Externa establishes long-term relationships with its clients, ensuring a steady stream of revenue aligned with client project timelines and deliverables.As part of its strategy for growth, exteRNA plans to enhance its platform and development capabilities utilizing the USD 11 million raised in Seed funding in October 2024. The company is focused on expanding its product offerings and exploring new geographical markets to increase its service reach. Specific target markets for expansion have not been disclosed, but the company aims to capitalize on its strong investor backing to drive innovation and customer acquisition.

## Funding rounds

- Seed, Oct 29, 2024, $11M — Longview Innovation, Hostplus, Walter And Eliza Hall Institute Of Medical Research, Tin Alley Ventures

## Investors

- Longview Innovation (https://capitalatlas.ai/funds/longview-innovation) — Seed
- Hostplus — Seed
- Walter And Eliza Hall Institute Of Medical Research — Seed
- Tin Alley Ventures — Seed